Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Leukemia 11Leukemia, Myeloid, Acute 9Lymphoma, Non-Hodgkin 7Lymphoma 7Myelodysplastic Syndromes 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma, Follicular 5Lymphoma, Mantle-Cell 4Lymphoma, Large-Cell, Immunoblastic 4Burkitt Lymphoma 4Blast Crisis 4Waldenstrom Macroglobulinemia 3Neoplasms 3Multiple Myeloma 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Myeloid, Chronic-Phase 3Leukemia, Myeloid, Accelerated Phase 3Leukemia, Lymphocytic, Chronic, B-Cell 3Hodgkin Disease 3Graft vs Host Disease 3Congenital Abnormalities 3Sezary Syndrome 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Extranodal NK-T-Cell 2Leukemia, Myelomonocytic, Juvenile 2Leukemia, Myelomonocytic, Chronic 2

Interventions

Nivolumab 13Ipilimumab 10pembrolizumab 8cemiplimab 6Surveys and Questionnaires 6Biopsy 6aldesleukin 5Radiotherapy 5Interleukin-2 5Blood Specimen Collection 5Temozolomide 4Sirolimus 4Photochemotherapy 4Mohs Surgery 4HhAntag691 4Fluorouracil 4Educational Status 4Cyclophosphamide 4sonidegib 3fludarabine phosphate 3fludarabine 3avelumab 3Vemurafenib 3Surgical Procedures, Operative 3Radiation 3Petrolatum 3Cetuximab 3Aminolevulinic Acid 3trametinib 2dabrafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Skin Neoplasms × Methylprednisolone Hemisuccinate × Clear all
NCT04305145 2026-01-29

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis

Massachusetts General Hospital

Phase 2 Active not recruiting
42 enrolled
Dermatologic

Colitis, Melanoma, Skin Neoplasms, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡